209 GSK Annual Report 2017 Strategic report Governance and remuneration Financial statements Investor information 39.
Contingent consideration liabilities The consideration for certain acquisitions includes amounts contingent on future events such as development milestones or sales performance.
The Group has provided for the fair value of this contingent consideration as follows: ShionogiViiV Novartis Healthcare Vaccines Other Total m m m m At 1 January 2015 1,684 40 1,724 Additions through business combinations 594 594 Remeasurement through income statement 1,874 111 1 1,986 Cash payments: operating cash flows 121 121 Cash payments: investing activities 38 300 338 Other movements 10 10 At 31 December 2015 3,409 405 41 3,855 Additions through business combinations 154 40 194 Remeasurement through income statement 2,162 152 33 2,281 Cash payments: operating cash flows 351 5 2 358 Cash payments: investing activities 66 7 73 Other movements 4 1 3 At 31 December 2016 5,304 545 47 5,896 Remeasurement through income statement 909 53 1 961 Cash payments: operating cash flows 587 7 594 Cash payments: investing activities 84 7 91 At 31 December 2017 5,542 584 46 6,172 Of the contingent consideration payable at 31 December 2017, 1,076 million 2016 561 million is expected to be paid within one year.
The contingent consideration payable in respect of the Novartis Vaccines business included a sales milestone of $450 million which was settled in January 2018.
The consideration payable for the acquisition of the Shionogi-ViiV Healthcare joint venture and the Novartis Vaccines business is expected to be paid over a number of years.
As a result, the total estimated liabilities are discounted to their present values, shown above.
The ShionogiViiV Healthcare contingent consideration liability is discounted at 8.5% and the Novartis Vaccines contingent consideration liability is discounted partly at 8% and partly at 9%.
The Shionogi-ViiV Healthcare contingent consideration liability is calculated based on the forecast sales performance of specified products, principally dolutegravir, over the life of those products.
The table below shows on an indicative basis the income statement and balance sheet sensitivity to reasonably possible changes in key inputs to the valuations of the contingent consideration liabilities.
ShionogiNovartis ViiV Healthcare Vaccines Increase decrease in financial liability and loss gain in Income statement m m 10% increase in sales forecasts 535 56 10% decrease in sales forecasts 535 55 1% increase in discount rate 228 18 1% decrease in discount rate 245 20 5% increase in probability of milestone success 6 5% decrease in probability of milestone success 6 10 cent appreciation of US Dollar 329 17 10 cent depreciation of US Dollar 284 15 10 cent appreciation of Euro 95 25 10 cent depreciation of Euro 80 21 An explanation of the accounting for ViiV Healthcare is set out on page 59.
